250 related articles for article (PubMed ID: 11147993)
1. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis.
Lange U; Teichmann J; Stracke H
Eur J Med Res; 2000 Dec; 5(12):507-11. PubMed ID: 11147993
[TBL] [Abstract][Full Text] [Related]
2. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
Choi ST; Kim JH; Kang EJ; Lee SW; Park MC; Park YB; Lee SK
Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
[TBL] [Abstract][Full Text] [Related]
4. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
5. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis.
Park MC; Lee SW; Choi ST; Park YB; Lee SK
Scand J Rheumatol; 2007; 36(2):101-6. PubMed ID: 17476615
[TBL] [Abstract][Full Text] [Related]
6. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
[TBL] [Abstract][Full Text] [Related]
7. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
Song IH; Rudwaleit M; Listing J; Sieper J
Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
[TBL] [Abstract][Full Text] [Related]
9. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
[TBL] [Abstract][Full Text] [Related]
10. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass.
Yazici S; Yazici M; Erer B; Erer B; Calik Y; Bulur S; Ozhan H; Ataoglu S
Platelets; 2010; 21(2):126-31. PubMed ID: 20050759
[TBL] [Abstract][Full Text] [Related]
11. Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arthritis and ankylosing spondylitis.
Rovensky J; Imrich R; Malis F; Zlnay M; Macho L; Koska J; Vigas M
J Rheumatol; 2004 Dec; 31(12):2418-21. PubMed ID: 15570644
[TBL] [Abstract][Full Text] [Related]
12. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
[TBL] [Abstract][Full Text] [Related]
13. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis.
Luc M; Gossec L; Ruyssen-Witrand A; Salliot C; Duclos M; Guignard S; Dougados M
J Rheumatol; 2007 Oct; 34(10):2078-81. PubMed ID: 17722225
[TBL] [Abstract][Full Text] [Related]
16. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
Korkosz M; Gąsowski J; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
Scand J Rheumatol; 2014; 43(1):43-8. PubMed ID: 24447112
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
18. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
[TBL] [Abstract][Full Text] [Related]
20. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
